AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (canceled).

2. (currently amended) A prodrug of the compound according to claim ~~1~~68.

3.-67. (canceled).

68. (currently amended) ~~The~~ A compound ~~according to claim 1, which is a compound of either~~ represented by the following ~~formula (I-A),~~ formula (I-B)~~, formula (I-C), formula (I-D) or formula (I-E)~~:






B
(R2)q
O
N
(R1)p
A
G
(I-C)
(R4)s
L
E
M–COOR5
t


B
(R2)q
O
N
(R1)p
A
G
N
(I-D)
(R4)s
L
E
M–COOR5
t



wherein R^1, R^2, R^3 and R^4 each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, ~~(3) C2-8 alkynyl, (4)~~(3) a halogen atom, ~~(5)~~(4) trihalomethyl, ~~(6) nitro, (7) cyano, (8)~~(5) Cyc1, ~~(9)~~(6) -OR^6, ~~(10) SR^7, (11) NR^8R^9, (12) $CONR^{10}R^{11}$, (13) $NR^{12}COR^{13}$, (14) $SO_2NR^{14}R^{15}$, (15) $NR^{16}SO_2R^{17}$, (16) SO_2R^{18}, (17) COR^{19}, (18) $COOR^{20}$,~~ or ~~(19)~~(7) C1-8 alkyl substituted with -OR^6, ~~SR^7, NR^8R^9~~ or Cycl;

R^6 represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, ~~(4) C2-8 alkynyl, (5)~~(4) Cycl, ~~(6)~~(5) methyl substituted with 1 to 3 halogen, or ~~(7)~~(6) C1-8 alkyl substituted with Cycl;

~~R^7 to R^{16} and R^{20} each independently represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) C2-8 alkynyl, or (5) Cycl;~~

~~R^{17}, R^{18} and R^{19} each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) C2-8 alkynyl, or (4) Cycl;~~

Cycl represents a C3-10 monocyclic or bicyclic carbocyclic group ~~or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s)~~;

G represents a bond,

K and M each independently represents (1) a bond, (2) C1-8 alkylene, or (3) C2-8 alkenylene~~, or (4) C2-8 alkynylene~~;

~~J represents a nitrogen atom or a carbon atom;~~

L represents a bond~~,~~ or an oxygen atom ~~or a sulfur atom~~;

Ring A~~, ring B and ring D each independently~~ represents a C3-10 monocyclic or bicyclic carbocyclic group~~ or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s)~~;

Ring B represents a C3-10 monocyclic or bicyclic carbocyclic group or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring D represents a C3-10 monocyclic carbocyclic group or a three- to ten-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring E represents a C3-7 monocyclic carbocyclic group~~ or a three- to seven-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s)~~;

p, q, r and s each independently represents 0 or an integer of from 1 to ~~5~~3,

in which R^1s are the same or different when p represents 2 or more; R^2s are the same or different when q represents 2 or more; R^3s are the same or different when r represents 2 or more; and R^4s are the same or different when s represents 2 or more, respectively;

t represents 0 or 1; and

R^5 represents (1) a hydrogen atom~~,~~ or (2) C1-8 alkyl, ~~(3) C2-8 alkenyl, or (4) C2-8 alkynyl,~~ or

a salt thereof.

69. (withdrawn-currently amended) A pharmaceutical composition comprising the compound according to claim ~~1~~68, a salt thereof or a prodrug thereof and a pharmaceutically acceptable carrier.

70. (withdrawn) The pharmaceutical composition according to claim 69, which is an LPA receptor antagonist.

71. (withdrawn) The pharmaceutical composition according to claim 70, wherein the LPA receptor is EDG-2 receptor.

72. (withdrawn) The pharmaceutical composition according to claim 71, which is an agent for prevention and/or treatment for urinary system disease.

73. (withdrawn) The pharmaceutical composition according to claim 71, which is an agent for prevention and/or treatment for carcinoma-associated disease, proliferative disease, inflammation / immune system disease, disease caused by secretory dysfunction or brain-related disease.

74. (withdrawn-currently amended) A method for prevention and/or treatment of diseases referred from EDG-2, which comprises administering an effective amount of the compound according to claim ~~1~~68, a salt thereof or a prodrug thereof to a mammal.

75. (withdrawn): The method for prevention and/or treatment according to claim 74, wherein the disease referred from EDG-2 is urinary system disease.

76. (withdrawn) The method for prevention and/or treatment according to claim 74, wherein the disease referred from EDG-2 is carcinoma-associated disease, proliferative disease, inflammation / immune system disease, disease caused by secretory dysfunction or brain-related disease.

Claims 77-79. (canceled).

80. (withdrawn-currently amended) A pharmaceutical composition for prevention and/or treatment of urinary system disease comprising a combination of an LPA receptor antagonist containing the compound according to claim ~~1~~68, a salt thereof or a prodrug thereof as an active ingredient and one or two more agent(s) selected from other LPA receptor

antagonist, α1 blocking agent, anticholinergic agent, 5α-reductase inhibitor and/or anti-androgenic agent.